Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer

European Journal of Cancer Prevention

Volumn 9, Issue 3, 2000, Pages 139-150

  Kuschel, B ^a   Lux, M P ^a   Goecke, T O ^a   Beckmann, M W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bilateral prophylactic mastectomy or oophorectomy; Chemoprevention; Familial breast cancer; High risk families; Ovarian and endometrial cancer

Indexed keywords

BREAST CANCER; CANCER RISK; CHEMOPROPHYLAXIS; FEMALE; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; RISK ASSESSMENT;

EID: 0034042020     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200006000-00001     Document Type: Review

References (81)

1. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D (1998). Survival in early onset BRCA1 breast-cancer patients. Lancet 352: 541.
2. Bailar JC, Gornik HL (1997). Cancer undefeated. N Engl J Med 336: 1569-74.
3. Baines CJ, Vidmar M, McKeown-Eyssen G, Tibshirani R (1997). Impact of menstrual phase on false-negative mammograms in the Canadian national breast screening study. Cancer 80: 720-4.
4. Bauer B, Veit R, Vogel E, Bernhardt JH (1997). Bildgebende Diagnostik der weiblichen Brust. Deutsches Ärzteblatt 94: A-2440-1.
5. Beckmann MW, Timmermann D (1997). Gibt es ein Populationsoder ein Risikogruppenscreening für das Ovarialkarzinom? Gynakologe 30: 85-91.
6. Beckmann MW, Schnuerch HG, Bodden-Heidrich R, et al. (1996). Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines. Eur J Cancer Prev 5: 468-75.
7. Beckmann MW, Untch M, Rabe T, Schulz KD, Bender HG (1999). Chemoprävention des Mammakarzinoms. Gynaekologe 32: 150-7
8. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G (1999). Mortality associated with oral contraceptive use: 25 years follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraceptive study. BMJ 318: 96-100.
9. Bick U (1997). An integrated early detection concept in women with a genetic predisposition for breast cancer. Radiologe 37: 591-6.
10. Bohmert HH (1988). Subcutaneous mastectomy. In Controversies in Breast Disease: Diagnosis and Management (eds Grundfest-Broniatowski S, Esselstyn CB); Marcel Dekker, New York, pp. 235-59.
11. Breast Cancer Linkage Consortium (1997). Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505-10.
12. Brinton LA, Daling JR, Liff JM, et al. (1995). Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 87: 827-35.
13. Brunet JS, Narod SA, Tonin P, Foulkes WD (1997). BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med 336: 1256.
14. Buller RE, Anderson B, Connor JP, Robinson R (1993). Familial ovarian cancer. Gynecol Oncol 51: 160-6.
15. Burke W, Daly M, Garber J, et al. (1997). Recommendations for follow-up care of individuals with inherited predisposition to cancer. JAMA 277: 997-1003.
16. Chang J, Fryatt I, Ponder BA, Fisher C, Gore ME (1995). A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome. Ann Oncol 6: 80-2.
17. Claus EB, Risch N, Thompson WD, Carter D (1993). Relationship between breast histopathology and family history of breast cancer. Cancer 71: 147-53.
18. Claus EB, Risch NJ, Thompson WD (1994). Autosomal dominant inheritance of early-onset breast cancer. Cancer 73: 643-51.
19. Collaborative Group on Hormonal Factors in Breast Cancer (1996). Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-27.
20. De Priest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR (1997). Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 65: 408-14.
21. Easton D (1997). Breast cancer genes - what are the real risks? Nature Genetics 17: 210-11.
22. Easton D, Ford D, Peto J (1993). Inherited susceptibility to breast cancer. Cancer Surv 18: 95-113.
23. Eisinger F, Jacquemier J, Charpin C, et al. (1998). Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58: 1588-92.
24. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW (1998). Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338: 1089-96.
25. Evans DGR, Anderson E, Lalloo F, et al. (1999). Utilisation of prophylactic mastectomy in 10 European centres. Disease Markers 15: 148-51.
26. Fearon ER (1997). Human cancer syndromes: clues to the origin and nature of cancer. Science 278: 1043-50.
27. Fisher B, Constantino JP, Wickerham L, et al. (1998). Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371-88.
28. Ford D, Easton DF, Stratton M, et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62: 676-89.
29. Gaffney DK, Brohet RM, Lewis CM, et al. (1998). Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 47: 129-36.
30. Goldberg JM, Piver MS, Mohannad FJ, Blumenson L (1997). Age at onset of ovarian cancer in women with a strong family history of ovarian cancer. Gynecol Oncol 66: 3-9.
31. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI (1998). Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16: 979-85.
32. Hartmann LC, Schaid DJ, Woods JE, et al. (1999). Efficacy of bilateral prophylactic mastectomy in women with family history of breast cancer. N Engl J Med 340: 77-84.
33. Hoskins KF, Stopfer JE, Calzone KA, et al. (1995). Assessment and counselling for women with family history of breast cancer. JAMA 273: 577-85.
34. Hughes KS, Papa MZ, Whitney T, McLellan R (1999). Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer 86 (suppl 11): 2502-16.
35. Humphrey LJ (1983). Subcutaneous mastectomy is not a prophylaxis against carcinoma of the breast: opinion and knowledge? Am J Surg 145: 311-12.
36. Ingvarsson S, Geirsdottir EK, Johannesdottir G, et al. (1998). High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation. Cancer Res 58: 4421-5.
37. Johannsson O, Idvall I, Anderson C, et al. (1997). Tumor biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33: 362-71.
38. Johannsson O, Loman N, Borg A, Olsson H (1998). Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 352: 1359-60.
39. Kerlikowske K, Grady D, Ernster V (1995). Benefit of mammography screening in women aged 40-49 years: current evidence from randomized controlled trials. Cancer 76: 1679-81.
40. Klijn JGM, Janin N (1997). Current controversies in cancer: should prophylactic surgery be used in women with a high risk of breast cancer? Eur J Cancer 33: 2149-59.
41. Lagios MD, Rose MR, Margolin FR (1980). Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma. Am J Clin Pathol 73: 25-30.
42. Lakhani S, Jacquemier J, Sloane JP, et al. (1998). Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90: 1138-45.
43. Law J (1997). Cancers detected and induced in mammographic screening: new screening schedules and younger women with family history. Br J Radiol 70: 62-9.
44. Lerman C, Hughes C, Lemon SJ, et al. (1998). What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 16: 1650-4.
45. Lyman GH, Kuderer NM (1997). Basic population and cancer genetics and their use in the assessment of cancer risk. Eur J Cancer 33: 2160-6.
46. Lynch HT, Lemon SJ, Durham C, et al. (1997). A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 79: 2219-28.
47. Marcus JN, Watson P, Page DL, et al. (1996). Hereditary breast cancer. Pathology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77: 697-709.
48. Montgomery LL, Tran KN, Heelan MC, et al. (1999). Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6 (suppl 6): 546-52.
49. Narod SA, Goldgar D, Cannon-Albright L, et al. (1995). Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 64: 394-8.
50. Narod S, Risch H, Moslehi R, et al. (1998). Oral contraceptive use reduces the risk of hereditary ovarian cancer. N Engl J Med 339: 424-8.
51. National Institutes of Health Consensus Development Panel (1997). Special article. National Institutes of Health Consensus Development Conference Statement: Breast cancer screening for women ages 40-49. J Natl Cancer Inst 89: 1015-26.
52. Osin P, Gusterson BA, Philp E, et al. (1998). Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 34: 1683-6.
53. Pennisi VR, Capozzi A (1989). Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 13: 15-21.
54. Petersson C, Pandis N, Mertens F, et al. (1996). Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families. Genes Chromosomes Cancer 16: 185-8.
55. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA (1999). Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res 59: 868-71.
56. Piver SM, Jishi MF, Tsukada Y, Nava G (1993). Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer 71: 2751-2755.
57. Powels T, Eeles R, Ashley S, et al. (1998). Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98-101.
58. Rebbeck TR, Levin AM, Eisen A, et al. (1999). Breast cancer risk after bilateral prophylactic oophorectomy in BRCA 1 mutation carriers. J Natl Cancer Inst 91: 1475-9.
59. Robson M, Gilewski T, Haas B, et al. (1998). BRCA-associated breast cancer in young women. J Clin Oncol 16: 1642-9.
60. Rubin SC, Benjamin I, Behbakht K, et al. (1996). Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335: 1413-16.
61. Salazar H, Godwin AK, Daly MB, et al. (1996). Microscopic benign and invasive malignant neoplasms and a cancer prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88: 1810-20.
62. Schmidt S, Becher H, Chang-Claude J (1998). Breast cancer risk assessment: use of complete pedigree information and the effect of misspecified ages at diagnosis of affected relatives. Hum Genet 102: 348-56.
63. Schmutzler RK, Kempe A, Kiechle M, Beckmann MW (1999). Gegenwärtiger Stand der klinischen Beratung und Betreuung von Frauen mit einer erblichen Disposition für das Mammakarzinom. Dtsch Med Wochenschr 124: 563-6.
64. Schrag D, Kuntz KM, Garber JE, Weeks JC (1997). Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336: 1465-71.
65. Schulz KD, Duda V, Schreer I, Heywang-Koebrunner SH (1997). Moeglichkeiten der Brustkrebsfrueherkennung. Gynaekologe 30: 631-6.
66. Steel CM (1995). Implications of studies of inherited predisposition for prevention and treatment. In The Genetics of Cancer. (eds Ponder BAJ, Waring MJ); Kluwer Academic Publishers, Dordrecht, pp. 159-75.
67. Stefanek ME, Helzlsouer KJ, Wilcox PM, Anp CS, Houn F (1995). Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 24: 412-19.
68. Stefanek M, Enger C, Benkendorf J, Flamm Honig S, Lerman C (1999). Bilateral prophylactic mastectomy decision making: a vignette study. Prev Med 29: 216-21.
69. Stratton JF, Buckley CH, Lowe D, Ponder BA (1999). Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of BRCA1 or BRCA2 gene mutation. J Natl Cancer Inst 91: 626-8.
70. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA (1995). Prophylactic oophorectomy in inherited breast/ovarian cancer families. Monogr Natl Cancer Inst 17: 33-5.
71. Teixeira MR, Pandis N, Gerdes AM, et al. (1996). Cytogenetic abnormalities in an in situ ductal carcinoma and five prophylactically removed breasts from members of family with hereditary breast cancer. Breast Cancer Res Treat 38: 177-82.
72. Tirkkonen M, Johannsson O, Agnarsson BA, et al. (1997). Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57: 1222-7.
73. Tobacman JK, Greene MH, Tucker MA, et al. (1982). Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet ii: 795-7.
74. Ursin G, Henderson BE, Haile RW, et al. (1997). Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/2 mutations? Cancer Res 57: 3678-81.
75. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. (1998). Survival and tumor characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 361: 316-21.
76. Veronesi U, Maisonneuve P, Costa A, et al. (1998). Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352: 93-7.
77. Werness BA, Afify AM, Bielat KL, et al. (1999). Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 30: 151-7.
78. Whittemore AS, Harris R, Itnyre J and the Collaborative Ovarian Cancer Group (1992). Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136: 1184-203.
79. Woods JE (1986). Breast reconstruction: current state of the art. Mayo Clin Proc 61: 579-85.
80. Wright JC, Weinstein MC (1998). Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 339: 380-6.
81. Ziegler LD, Kroll SS (1991). Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 14: 451-4.